Disappointing BRAVO Data Raise Doubts About Laquinimod’s Chances
This article was originally published in Pharmaceutical Approvals Monthly
Teva Pharmaceuticals Co. Ltd. is facing investor doubts about regulatory prospects for its oral multiple sclerosis drug laquinimod after the drug missed the primary endpoint in a second Phase III trial, called BRAVO.
You may also be interested in...
Top-line results from a Phase IIb trial of Biogen Idec Inc./Abbott Laboratories Inc.'s daclizumab in relapsing-remitting multiple sclerosis are impressive, but data from an ongoing Phase III trial may clear up lingering questions about the drug's safety profile.
Merck KGaA ends development of oral cladribine tablets following rejection by European and U.S. regulators.
Teva's Phase III ALLEGRO study shows the once-daily oral multiple sclerosis candidate still has promise, but efficacy data underwhelms.